Recorded fact · drug.label_indication
drug.label_indication for insulin-glargine-lixisenatide|type-2-diabetes
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 4aa546b6 resolves to.
The record
| Fact id | 4aa546b67d7f1ce63016a7fa |
|---|---|
| Entity | drug: insulin-glargine-lixisenatide|type-2-diabetes |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260318 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 9a8db06cdb4e7a9b86332fe6c6f01e34ae426a9f527c6e8018109d1f5c24ccb8.
The value
{
"ingredient": "Insulin Glargine/Lixisenatide",
"conditionId": "type-2-diabetes",
"conditionName": "Type 2 diabetes",
"matchedAlias": "type 2 diabetes",
"context": "indication",
"brand": "Soliqua 100/33",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "4bba538b-cf7c-4310-ae8f-cb711ed21bcc",
"labelEffectiveTime": "20260318",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 27cd55c1c630e24deb71440fb28be31aebd7c08890003925b046cac9254a6d59.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.